Plain-English translation of NCT05902988 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage clinical trial testing a new medication called , which works by targeting a specific protein involved in cancer cell growth. The trial is designed in two phases: first, researchers will carefully increase the dose in patients to find the highest safe amount, then expand testing in larger groups of patients with specific cancer types to see how well the medication works.
Many patients with advanced cancers run out of standard treatment options or develop resistance to existing therapies. This medication represents a new approach to treating several difficult-to-treat cancers, and this trial is the first step in determining whether it could become a meaningful new option for patients who need it most.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth in 28-day cycles and return for regular clinic visits to check on your health and how the cancer is responding. During the first phase of the trial, your dose may be adjusted based on how well you tolerate the medication and any side effects you experience. You will have blood tests, scans, and other tests to monitor your progress, and you will continue treatment until your cancer progresses, you experience unacceptable side effects, or another stopping point is reached.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States